Aquestive Therapeutics, Inc., known as AQST, is a renowned specialty pharmaceutical company focusing on the advancement and commercialization of medicines designed to solve critical healthcare challenges. Founded in 2004 and based in Warren, New Jersey in the United States, AQST addresses these challenges through two prongs – developing advanced pharmaceutical technologies and incorporating these technologies into novel treatment plans.
The primary commitment of Aquestive Therapeutics is to provide better treatment options for people living with central nervous disorders and other conditions. Using the power of modern pharmaceutical technology, AQST aims to enhance the lives of patients by delivering these therapeutics in ways that sidestep the drawbacks of current methodologies.
The unique aspect of Aquestive Therapeutics is the creation of an advanced, patented drug delivery system called PharmFilm®. This technology allows the company to deliver a wide array of drugs orally without the need of drinking or swallowing. Therefore, it is a significant breakthrough for patients who have difficulty swallowing.
The portfolio of AQST boasts some noteworthy products targeting a range of conditions. A leading product of the company, Sympazan®, is an oral soluble film indicated for the treatment of Lennox-Gastaut Syndrome, a severe form of childhood epilepsy. The firm is also researching several other drugs for diseases like amyotrophic lateral sclerosis (ALS) and Parkinson's disease, contributing significantly to the future of the healthcare industry.
Aquestive Therapeutics, Inc. operates with a clear vision – offering innovative, high-value products that improve patients' lives. Through its advanced technology and rigorous research, it upholds an unwavering commitment to patient care and therapeutic excellence. Aquestive Therapeutics stands out in the pharmaceutical field for its transformative and patient-friendly treatments, reflecting the company's dedication to its mission of bettering healthcare.
Despite enduring financial and regulatory challenges in recent years, AQST continues to display significant progress in the medical and technological fields. Through collaborations and partnerships with other organizations, Aquestive Therapeutics is making its mark on the pharmaceutical industry, expecting to bring about novel treatments that will change the lives of patients worldwide. With cutting-edge technologies, extensive research, and relentless dedication to transforming patient care, AQST is undoubtedly a champion in its field, destined for continued growth and innovation.